Cohort | n | Sex, M:F | Age, yrs, Range (Median) | Antinuclear Antibody* | Anti-DFS70–positive, n (%) | Other Autoantibody–positive, n (%) | ||
---|---|---|---|---|---|---|---|---|
Positive, n (%) | Range (Median) | DFS Pattern–positive, n (%) | ||||||
Juvenile DM | 29 | 11:18 | 1–16 (9) | 23 (79.3) | 1/40–1/320 (× 80) | 8 (27.6) | 8 (27.6) | Anti-TIF1-γ, 9 (31.0) Anti-MDA5, 8 (27.6) Anti-PMS1, 6 (20.7) Anti-NXP2, 5 (17.2) Anti-MLH1, 3 (10.3) |
Localized scleroderma | 14 | 2:12 | 3–18 (12) | 13 (92.9) | 1/40–1/640 (× 80) | 0 (0) | 0 (0) | Anti-ssDNA, 9 (64.3) |
JIA with iridocyclitis | 10 | 4:6 | 1–11 (6) | 10 (100) | 1/40–1/640 (× 160) | 4 (40) | 5 (50) | NT |
↵* Antinuclear antibody also includes anticytoplasmic antibody. DFS: dense fine speckled; DM: dermatomyositis; JIA: juvenile idiopathic arthritis; NT: not tested; anti-TIF1-γ: antitranscriptional intermediary factor 1-γ.